Tesamorelin
Well StudiedGHRH analog
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that has been studied in endocrinology research. It has been investigated for its effects on growth hormone secretion and its role in metabolic pathways. Published research has examined its pharmacological properties and receptor interactions. RaysunPeptide supplies Tesamorelin for qualified research and laboratory applications.
Mechanism of Action
Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat.
Key Benefits
Molecular Data
Dosing Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| HIV Lipodystrophy (FDA-approved) | 1.4mg | Once daily | SubQ |
| Visceral Fat Reduction | 2mg | Once daily | SubQ |
| Anti-aging/Body Composition | 1-2mg | 5-7x weekly | SubQ |
| NAFLD Treatment | 2mg | Once daily (12 months) | SubQ |
| Cognitive Enhancement | 1mg | Once daily (20 weeks) | SubQ |
Research Indications
Weight Loss
FDA-approved indication showing 15-20% visceral fat reduction in clinical trials.
Unique mechanism that reduces dangerous visceral fat while sparing subcutaneous fat.
Maintained weight loss with continuous treatment over 52+ weeks in clinical studies.
Metabolic
12.3% reduction in triglyceride levels.
7.2% improvement in cholesterol markers.
37% liver fat reduction over 12 months.
Body Composition
Preserves lean muscle mass during fat loss.
26% increase in IGF-1 levels.
Peptide Interactions
Synergistic GH stimulation; monitor IGF-1 levels.
Combined use may elevate IGF-1 supraphysiologically.
Similar mechanism; risk of excessive effects at higher doses.
3.3-fold diabetes risk increase; monitor glucose closely.
May mitigate glucose intolerance associated with tesamorelin.
Decreases corticosteroid effectiveness.
Blocks GH release, negates tesamorelin effects.
Redundant; risk of acromegaly-like effects.
What to Expect
Side Effects & Safety
Common (Generally Mild)
- •Injection site reactions (17%)
- •Joint pain (13%)
- •Water retention
Stop Signs (Seek Medical Attention)
- ⚠Development of diabetes or severe glucose intolerance (HbA1c ≥6.5%)
- ⚠Signs of malignancy
- ⚠Severe hypersensitivity reactions
- ⚠Excessive IGF-1 elevation (>2 SD above normal) with acromegaly symptoms
Contraindications
- ✕Active malignancy
- ✕Pituitary disorders
- ✕Pregnancy
Quality Checklist
Good Signs ✓
- FDA-approved formulations (Egrifta SV/WR from licensed pharmacy)
- White crystalline powder (uniform, cake-like)
- Clear reconstituted solution (colorless, no particles)
- Proper packaging (sealed vials, intact stoppers)
Warning Signs !
- Compounded formulations may have quality/potency variability
Bad Signs ✕
- Discolored or cloudy solution (yellow/brown indicates degradation)
- Visible particles or precipitate
References
Pivotal Phase III trial in 412 HIV patients. Tesamorelin 2mg daily for 26 weeks significantly decreased visceral fat and improved lipid profiles compared to placebo.
View on PubMed →404 HIV patients treated for up to 12 months. 69% achieved ≥8% VAT reduction vs 33% placebo. VAT benefits were lost upon discontinuation, confirming need for continuous therapy.
View on PubMed →152 adults (ages 55-87) treated with tesamorelin 1mg daily for 20 weeks. Favorable effect on cognition (P=0.03), with particular benefit on executive function (P=0.005) and IGF-1 increase of 117%.
View on PubMed →61 HIV patients with NAFLD randomized to tesamorelin 2mg vs placebo for 12 months. 37% relative reduction in hepatic fat fraction (P=0.02), with prevention of fibrosis progression on liver biopsy.
View on PubMed →Meta-analysis of 5 RCTs showing significant VAT reduction (MD=-27.71 cm², P<0.001), increased lean body mass (MD=1.42 kg, P<0.001), and improved hepatic fat and IGF-1 levels without serious safety concerns.
View on PubMed →FAQs
Does tesamorelin specifically target visceral fat or does it reduce overall body fat?
Tesamorelin uniquely targets visceral (deep abdominal) fat while sparing subcutaneous fat. This selective mechanism makes it FDA-approved specifically for HIV-associated lipodystrophy - the visceral fat reduction of 15-20% occurs without proportional subcutaneous fat loss, improving metabolic health and reducing cardiovascular risk.
Can tesamorelin improve cognitive function or is that just a side benefit?
Cognitive improvement isn't a primary effect, but a Phase 2 trial in 152 older adults (55-87 years) showed favorable effects on cognition, particularly executive function (P=0.005), with 117% IGF-1 increases. This suggests potential anti-aging brain benefits, though larger trials are needed for confirmation.
Does tesamorelin increase diabetes risk like other GH therapies?
Yes, tesamorelin carries a documented 3.3-fold increased diabetes risk compared to placebo. Close glucose monitoring is essential, especially in pre-diabetic patients. Metformin co-treatment may mitigate this risk, and diabetics require careful medication adjustment.
Why use tesamorelin over semaglutide for visceral fat loss?
Tesamorelin uniquely spares subcutaneous fat while targeting visceral fat, making it better for patients wanting to preserve healthy fat deposits. Semaglutide causes general weight loss across all fat depots. Choose tesamorelin for selective visceral fat reduction in metabolically healthy individuals; semaglutide for comprehensive weight loss.
